257 related articles for article (PubMed ID: 11418381)
1. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update.
Vigorito AC; Marques Júnior JF; Aranha FJ; Oliveira GB; Miranda EC; De Souza CA
Haematologica; 2001 Jun; 86(6):665-6. PubMed ID: 11418381
[No Abstract] [Full Text] [Related]
2. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
Nivison-Smith I; Bradstock KF; Szer J; Durrant S; Dodds A; Hermann R; Schwarer AP; Gibson J; To LB; Arthur C;
Bone Marrow Transplant; 2001 Jul; 28(1):21-7. PubMed ID: 11498740
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
6. Is there an upper age limit for bone marrow transplantation?
Popplewell LL; Forman SJ
Bone Marrow Transplant; 2002 Feb; 29(4):277-84. PubMed ID: 11896423
[TBL] [Abstract][Full Text] [Related]
7. Chronic graft-versus-host disease following allogeneic peripheral blood and bone marrow stem cell transplants: a single center experience.
Takami A; Ishiyama K; Asakura H; Shiobara S; Nakao S
Haematologica; 2002 Jun; 87(6):664-6. PubMed ID: 12031928
[No Abstract] [Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
10. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
11. Serum interferon-gamma and C-reactive protein levels as predictors of acute graft-vs-host disease in allogeneic hematopoietic precursor cell (marrow or peripheral blood progenitor cells) recipients.
Lange A; Karabon L; Klimczak A; Dłubek D; Bogunia-Kubik K; Swider C; Suchnicki K
Transplant Proc; 1996 Dec; 28(6):3522-5. PubMed ID: 8962369
[No Abstract] [Full Text] [Related]
12. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
[TBL] [Abstract][Full Text] [Related]
13. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
14. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
15. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease.
Ostronoff M; Ostronoff F; Souto Maior P; Matias C; Calixto R; Sucupira A; Domingues M; Florencio R; Tagliari C
Biol Blood Marrow Transplant; 2006 Jul; 12(7):729-33. PubMed ID: 16785062
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies. AIEOP-BMT Group (Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant Group).
Miniero R; Busca A; Pession A; Rondelli R; Uderzo C; Ripaldi M; Locatelli F
Haematologica; 1999 Jul; 84(7):657-60. PubMed ID: 10406913
[No Abstract] [Full Text] [Related]
18. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
[TBL] [Abstract][Full Text] [Related]
20. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
